Peritoneal surface malignancies (PSM) are a clinical entity with an unfavourable prognosis.They comprise peritoneal carcinomatosis,pseudomyxoma peritonei,and primitive tumors of the peritoneum.Because the treatment of...Peritoneal surface malignancies (PSM) are a clinical entity with an unfavourable prognosis.They comprise peritoneal carcinomatosis,pseudomyxoma peritonei,and primitive tumors of the peritoneum.Because the treatment of PSM presents unique and challenging problems to the cancer clinician,many new approaches have been attempted in recent years.In the current and next issues of World Journal of Gastrointestinal Oncology,some international groups of researchers discuss the most important and innovative aspects of PSM treatment,with particular accuracy for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.In conclusion,because this new approach to PSM has a reputation for being based more on common sense than on experimental data,I hope that highlighting this topic can make a contribution to the treatment of this group of diseases.展开更多
目的:观察紫杉醇腹腔灌注联合全身化疗治疗晚期胃癌合并恶性腹腔积液的疗效及安全性。方法:选取晚期胃癌伴恶性腹水患者60例,随机分为紫杉醇组和顺铂组,紫杉醇组30例,顺铂组30例,分别于腹腔积液引流干净后,给予腹腔内灌注紫杉醇或顺铂,...目的:观察紫杉醇腹腔灌注联合全身化疗治疗晚期胃癌合并恶性腹腔积液的疗效及安全性。方法:选取晚期胃癌伴恶性腹水患者60例,随机分为紫杉醇组和顺铂组,紫杉醇组30例,顺铂组30例,分别于腹腔积液引流干净后,给予腹腔内灌注紫杉醇或顺铂,灌注3次为1个疗程,2个疗程后评价疗效,2组均同时联合两药方案行全身化疗,分析2组纳入观察病例的临床疗效及安全性。结果:所有患者均可评价:紫杉醇组有效率(response rate,RR)为60.0%,疾病控制率(disease control rate,DCR)为83.3%,中位肿瘤进展时间(time to progress,TTP)为10个月,KPS评分为(78.000±13.235)分;顺铂组RR为40.0%,DCR为73.3%,中位TTP为7个月,KPS评分为(71.000±13.222)分。紫杉醇组的疗效有优于顺铂组的趋势,无统计学差异(Z=-1.245,P=0.213);2组治疗后TTP以及KPS的改善差异均有统计学意义(χ^2=15.864,P=0.000;Z=-2.067,P=0.039)。2组主要不良反应有骨髓抑制、恶心呕吐、腹痛、腹泻、肌肉关节痛、口腔黏膜炎等,症状均较轻,予对症处理可缓解,不影响治疗。未见过敏反应及明显的肝肾功能损害,无治疗相关性死亡(P>0.05)。结论:紫杉醇腹腔灌注化疗治疗合并恶性腹水的晚期胃癌较顺铂组有更好的疗效,且药物毒副作用小,患者耐受性良好,能更好地改善患者生活质量,延长TTP。展开更多
文摘Peritoneal surface malignancies (PSM) are a clinical entity with an unfavourable prognosis.They comprise peritoneal carcinomatosis,pseudomyxoma peritonei,and primitive tumors of the peritoneum.Because the treatment of PSM presents unique and challenging problems to the cancer clinician,many new approaches have been attempted in recent years.In the current and next issues of World Journal of Gastrointestinal Oncology,some international groups of researchers discuss the most important and innovative aspects of PSM treatment,with particular accuracy for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.In conclusion,because this new approach to PSM has a reputation for being based more on common sense than on experimental data,I hope that highlighting this topic can make a contribution to the treatment of this group of diseases.
文摘目的:观察紫杉醇腹腔灌注联合全身化疗治疗晚期胃癌合并恶性腹腔积液的疗效及安全性。方法:选取晚期胃癌伴恶性腹水患者60例,随机分为紫杉醇组和顺铂组,紫杉醇组30例,顺铂组30例,分别于腹腔积液引流干净后,给予腹腔内灌注紫杉醇或顺铂,灌注3次为1个疗程,2个疗程后评价疗效,2组均同时联合两药方案行全身化疗,分析2组纳入观察病例的临床疗效及安全性。结果:所有患者均可评价:紫杉醇组有效率(response rate,RR)为60.0%,疾病控制率(disease control rate,DCR)为83.3%,中位肿瘤进展时间(time to progress,TTP)为10个月,KPS评分为(78.000±13.235)分;顺铂组RR为40.0%,DCR为73.3%,中位TTP为7个月,KPS评分为(71.000±13.222)分。紫杉醇组的疗效有优于顺铂组的趋势,无统计学差异(Z=-1.245,P=0.213);2组治疗后TTP以及KPS的改善差异均有统计学意义(χ^2=15.864,P=0.000;Z=-2.067,P=0.039)。2组主要不良反应有骨髓抑制、恶心呕吐、腹痛、腹泻、肌肉关节痛、口腔黏膜炎等,症状均较轻,予对症处理可缓解,不影响治疗。未见过敏反应及明显的肝肾功能损害,无治疗相关性死亡(P>0.05)。结论:紫杉醇腹腔灌注化疗治疗合并恶性腹水的晚期胃癌较顺铂组有更好的疗效,且药物毒副作用小,患者耐受性良好,能更好地改善患者生活质量,延长TTP。
